Probenecid

Dosage for Probenecid must be highly individualized based on the patient's renal function, serum uric acid levels, and the specific condition being treated.

Chronic Gouty Arthritis

• Initial Phase: The typical starting dose is 250 mg (half of a 500 mg tablet) taken twice daily for the first week. This low starting dose is intended to prevent a sudden drop in uric acid levels, which can paradoxically trigger an acute gout flare.
• Maintenance Phase: After one week, the dose is usually increased to 500 mg twice daily. If serum urate levels remain high (above 6 mg/dL), the healthcare provider may increase the dose by 500 mg increments every 4 weeks, up to a maximum of 2,000 mg (2 grams) per day, divided into two or four doses.
• Long-term Management: Once the patient has been symptom-free for several months and urate levels are stable, the provider may attempt to reduce the dose by 500 mg every 6 months to find the lowest effective maintenance dose.

Adjuvant Antibiotic Therapy

• General Use: The standard dose is 500 mg four times daily (2,000 mg total per day).
• Neurosyphilis: When used with aqueous crystalline penicillin G, the dose is typically 500 mg four times daily for 10 to 14 days.
• Pelvic Inflammatory Disease (PID): A single dose of 1 gram of Probenecid is often given concurrently with a single dose of Cefoxitin as part of an outpatient regimen.

Probenecid is generally contraindicated in children under the age of 2 years.

• Children (2-14 years): When used as an adjuvant to penicillin therapy, the initial dose is typically 25 mg/kg of body weight. The maintenance dose is 40 mg/kg per day, divided into four equal doses. For children weighing more than 50 kg (110 lbs), the adult dosage of 2 grams per day is usually applied.
• Gout: Pediatric gout is rare and usually associated with underlying metabolic disorders; dosing in these cases must be managed by a pediatric rheumatologist or nephrologist.

Renal Impairment

Probenecid is not recommended for patients with severe renal impairment (Creatinine Clearance < 30 mL/min). In patients with moderate renal impairment (CrCl 30-50 mL/min), the uricosuric effect is significantly reduced, and higher doses may be required, although the risk of toxicity also increases. Your doctor will perform regular kidney function tests (BUN and Creatinine) to determine if the drug is appropriate for you.

Hepatic Impairment

While there are no specific dosage adjustment guidelines for liver disease, Probenecid is extensively metabolized in the liver. Patients with significant hepatic dysfunction should be monitored closely for signs of drug accumulation.

Elderly Patients

Older adults often have age-related declines in renal function. Healthcare providers typically start at the lower end of the dosing spectrum and monitor kidney function frequently.

• Hydration: This is the most critical instruction. You must drink at least 2 to 3 liters (about 8 to 12 cups) of water daily while taking Probenecid. This helps prevent the formation of uric acid kidney stones in the urinary tract.
• With Food: To prevent stomach upset, take Probenecid with a full glass of water and food or an antacid.
• Consistency: Take the medication at the same time each day to maintain steady levels in your blood.
• Alkalinization: In some cases, your doctor may prescribe sodium bicarbonate or potassium citrate to make your urine less acidic, which further prevents kidney stones.

If you miss a dose of Probenecid, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this increases the risk of gastrointestinal side effects and kidney irritation.

Signs of a Probenecid overdose may include severe nausea, vomiting, stomach pain, tremors, seizures, or respiratory distress. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining airway patency and managing seizures if they occur.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to a severe gout flare or treatment failure in infections.

Most patients tolerate Probenecid well, but the most frequently reported side effects involve the gastrointestinal system. These include:

• Nausea and Vomiting: This is the most common complaint. It usually occurs shortly after taking the dose and can often be managed by taking the medication with food.
• Loss of Appetite (Anorexia): Some patients experience a decreased desire to eat, which typically resolves as the body adjusts to the medication.
• Headache: Mild to moderate headaches may occur during the first few weeks of therapy.
• Dizziness: A sensation of lightheadedness or spinning, especially when rising quickly from a seated position.

• Gout Flares: Paradoxically, starting Probenecid can trigger an acute attack of gout. This happens because the rapid lowering of serum uric acid causes urate crystals in the joints to mobilize or 'dissolve,' leading to temporary inflammation.
• Urinary Frequency: Increased urination is common due to the drug's effect on renal transport and the requirement for high fluid intake.
• Sore Gums: Some patients report mild swelling or sensitivity in the gingival tissues.
• Flushing: A temporary reddening of the face or neck.

• Dermatitis and Pruritus: Skin rashes or intense itching may occur and may indicate a mild allergic reaction.
• Alopecia: Thinning of the hair has been reported in rare instances.
• Anemia: A decrease in red blood cell count, which may cause fatigue or paleness.
• Fever: Unexplained low-grade fever.

> Warning: Stop taking Probenecid and call your doctor immediately if you experience any of these serious conditions.

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the face, tongue, or throat, difficulty breathing, and a rapid drop in blood pressure.
• Nephrotic Syndrome: Damage to the kidney's filtering units, resulting in severe swelling (edema) in the ankles or feet and foamy urine (proteinuria).
• Hepatic Necrosis: Serious liver damage. Symptoms include yellowing of the skin or eyes (jaundice), dark urine, and severe upper abdominal pain.
• Aplastic Anemia or Leukopenia: A dangerous drop in white blood cells or all blood cell types, which can lead to severe infections or uncontrolled bleeding. Symptoms include unexplained bruising, sore throat, or persistent fever.
• Hemolytic Anemia: Particularly in patients with G6PD deficiency, Probenecid can cause the rapid destruction of red blood cells.
• Renal Colic: Intense, stabbing pain in the side or back (flank pain), which may indicate the formation of a uric acid kidney stone.

• Urolithiasis (Kidney Stones): The primary long-term risk of Probenecid is the formation of uric acid stones in the urinary tract. This risk is highest during the first few months of therapy when uric acid excretion is at its peak. Long-term adherence to high fluid intake is mandatory.
• Renal Function Changes: While Probenecid is used to manage gout, chronic use in patients with pre-existing kidney disease requires careful monitoring to ensure the drug itself is not contributing to a decline in renal function.

No FDA black box warnings are currently issued for Probenecid. However, the lack of a black box warning does not imply the drug is without risk; the potential for severe hypersensitivity and renal complications remains a primary clinical concern.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular blood and urine tests are necessary to monitor for these side effects.

Probenecid is a potent metabolic modifier and must be used with caution. The most critical safety instruction for any patient starting Probenecid is the maintenance of high fluid intake. Because the drug works by forcing the kidneys to dump uric acid into the urine, the concentration of urate in the urinary tract can become high enough to crystallize into stones. This can lead to kidney damage or severe pain. Patients must also be aware that Probenecid is not an analgesic (painkiller) and will not provide relief during an acute gout attack.

There are currently no FDA black box warnings for Probenecid. It is considered a relatively safe medication when used according to established guidelines and with proper patient monitoring.

• Hypersensitivity Risk: Patients with a history of allergic reactions to sulfonamides may have an increased risk of reacting to Probenecid, although they are chemically distinct. Any sign of a rash or breathing difficulty requires immediate cessation of the drug.
• G6PD Deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at a significant risk of hemolytic anemia (destruction of red blood cells) when taking Probenecid. This is a genetic condition more common in individuals of African, Mediterranean, or Asian descent.
• Peptic Ulcer Disease: Probenecid should be used with extreme caution in patients with a history of stomach ulcers, as the drug can irritate the gastrointestinal lining and potentially reactivate an ulcer.
• Acute Gout Flare: Starting Probenecid during an active gout flare is contraindicated. It is recommended to wait at least 2 to 4 weeks after an attack has subsided before beginning therapy. Often, doctors will co-prescribe low-dose colchicine or an NSAID for the first 3 to 6 months of Probenecid therapy to prevent these flares.
• Renal Insufficiency: The drug loses its effectiveness as kidney function declines. It may not work at all in patients with a creatinine clearance below 30 mL/min.

Patients on long-term Probenecid therapy require regular laboratory monitoring:

• Serum Uric Acid: Tested every few weeks during dose titration and every 6-12 months once stable.
• Renal Function (BUN/Creatinine): To ensure the kidneys are healthy enough to process the drug.
• Complete Blood Count (CBC): To monitor for rare blood disorders like anemia or leukopenia.
• Urinary pH: Occasionally, a doctor may check the acidity of the urine to ensure it is not too acidic, which increases stone risk.

Probenecid may cause dizziness or headaches in some patients. Until you know how this medication affects you, use caution when driving, operating heavy machinery, or performing tasks that require mental alertness.

Alcohol consumption, particularly beer and hard liquor, should be strictly limited. Alcohol increases the production of uric acid and interferes with its excretion, effectively working against the mechanism of Probenecid. Furthermore, alcohol can increase the risk of gastrointestinal irritation when combined with this medication.

Do not stop taking Probenecid suddenly without consulting your doctor. Discontinuing the drug can cause a rapid rebound in uric acid levels, leading to a severe gout flare. If the drug must be stopped, it is often tapered or replaced with another urate-lowering therapy like allopurinol.

> Important: Discuss all your medical conditions, especially kidney disease, stomach ulcers, or blood disorders, with your healthcare provider before starting Probenecid.

• Salicylates (Aspirin): This is the most significant interaction. Even low doses of aspirin (such as 81 mg 'baby' aspirin) can completely antagonize (block) the uricosuric effect of Probenecid. This means Probenecid will stop working to lower uric acid levels. Conversely, Probenecid can increase the blood levels of salicylates to toxic levels. Patients needing cardiovascular protection should discuss alternatives like clopidogrel with their doctor.
• Ketorolac: Probenecid significantly increases the plasma levels and half-life of ketorolac, greatly increasing the risk of gastrointestinal bleeding and acute kidney failure.

• Methotrexate: Probenecid inhibits the renal secretion of methotrexate, a drug used for cancer and rheumatoid arthritis. This can lead to a dangerous accumulation of methotrexate, resulting in severe bone marrow suppression and organ toxicity. This combination should generally be avoided unless under strict specialist supervision.
• NSAIDs (Naproxen, Indomethacin, Ibuprofen): Probenecid can increase the blood levels of many NSAIDs. While they are often used together to prevent gout flares, the dose of the NSAID may need to be reduced to prevent side effects like stomach ulcers or kidney strain.
• Antivirals (Acyclovir, Valacyclovir, Ganciclovir): Probenecid reduces the renal clearance of these drugs, potentially increasing their side effects, such as neurotoxicity or kidney crystals.

• Lorazepam: Probenecid may decrease the metabolism of lorazepam, leading to increased sedation and respiratory depression.
• Sulfonylureas (Glipizide, Glyburide): Probenecid can increase the effects of these diabetes medications, potentially leading to hypoglycemia (low blood sugar).
• Dapsone: Increased levels of dapsone can lead to a higher risk of methemoglobinemia (a blood disorder).

• High-Purine Foods: While not a direct drug-drug interaction, consuming foods high in purines (red meat, organ meats, seafood like sardines and mussels) increases uric acid production and reduces the efficacy of Probenecid therapy.
• Hydration: As previously noted, inadequate water intake is a 'negative interaction' that increases the risk of renal stones.
• Caffeine: Large amounts of caffeine may have a mild diuretic effect, which could complicate the hydration status required for Probenecid therapy.

• Vitamin C: High doses of Vitamin C can acidify the urine, which increases the risk of uric acid stones while taking Probenecid.
• Ginkgo Biloba: May have anti-platelet effects that, when combined with the potential for GI irritation from Probenecid, could theoretically increase bleeding risk.

• Urinary Glucose: Probenecid can cause a false-positive result for glucose in the urine when using copper reduction tests (like Clinitest). It does not affect glucose oxidase tests (like Diastix or Chemstrip).
• 17-Ketosteroids: Probenecid may decrease the urinary excretion of these steroids, leading to falsely low lab readings.

For each interaction, the primary mechanism is the inhibition of renal organic anion transporters (OATs) or the competition for glucuronidation pathways in the liver. The clinical consequence is almost always an increase in the secondary drug's concentration, leading to potential toxicity.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is essential before starting Probenecid.

Probenecid must NEVER be used in the following circumstances:

• Known Hypersensitivity: If a patient has had a previous severe allergic reaction to Probenecid or any component of the tablet.
• Children Under 2 Years: The safety and efficacy of Probenecid in infants have not been established, and their renal transport systems are not fully developed.
• Uric Acid Kidney Stones (Urolithiasis): If a patient has a history of stones made of uric acid, Probenecid is contraindicated because it will significantly increase the amount of uric acid in the urine, making more stones almost certain.
• Blood Dyscrasias: Patients with active blood disorders, such as aplastic anemia or low white blood cell counts, should not use Probenecid due to the risk of exacerbating these conditions.
• Acute Gout Attack: Starting the drug during an attack can worsen the inflammation and prolong the pain.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Moderate Renal Impairment: If the Creatinine Clearance is between 30 and 50 mL/min, the drug may be used with caution, but its effectiveness is questionable.
• Peptic Ulcer History: The risk of GI bleed or ulcer reactivation must be weighed against the benefits of urate lowering.
• G6PD Deficiency: Due to the risk of hemolytic anemia, alternative gout medications like allopurinol are usually preferred.

While Probenecid is not a sulfonamide, it contains a sulfonamide moiety in its chemical structure. There have been rare reports of cross-sensitivity in patients allergic to 'sulfa' drugs (like Bactrim). While most sulfa-allergic patients can safely take Probenecid, they should be monitored closely for the first few doses.

> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and allergy history, before prescribing Probenecid.

Probenecid is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, Probenecid should be used during pregnancy only if clearly needed. It is generally not recommended for the treatment of gout during pregnancy, as gout is rare in women of childbearing age and other management strategies are usually preferred. If used as an adjuvant for syphilis treatment in a pregnant woman, the benefits of treating the infection usually outweigh the potential risks to the fetus.

It is not known whether Probenecid is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Probenecid, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most clinicians recommend caution and monitoring the infant for gastrointestinal upset or skin rashes if the mother must take the medication.

Probenecid is approved for use in children aged 2 years and older, primarily as an adjuvant to penicillin therapy for serious infections. It is not commonly used for gout in children unless they have specific metabolic disorders (like Lesch-Nyhan syndrome). The main concern in pediatric use is ensuring the child remains adequately hydrated to prevent kidney stones, which can be difficult in younger children.

Clinical studies of Probenecid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function, dose selection should be cautious. The risk of drug-drug interactions is also significantly higher in this population due to polypharmacy (taking multiple medications). Regular monitoring of the glomerular filtration rate (GFR) is essential.

In patients with renal insufficiency, the uricosuric effect of Probenecid is diminished. If the GFR is less than 30 mL/min, the drug is generally considered ineffective. Furthermore, Probenecid may not be cleared effectively, leading to higher systemic levels and increased risk of side effects. It is not removed by hemodialysis to any significant degree.

No specific studies have been conducted in patients with hepatic impairment. However, since the liver is the primary site of metabolism for Probenecid, patients with Child-Pugh Class B or C cirrhosis should be monitored for signs of toxicity. There is a rare risk of hepatic necrosis associated with Probenecid use, which may be higher in those with pre-existing liver disease.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or have underlying kidney or liver issues.

Probenecid is a competitive inhibitor of the organic anion transport system in the renal tubule. Specifically, it inhibits the URAT1 (Urate Transporter 1) protein located on the apical membrane of the proximal tubule cells. URAT1 is the primary mechanism by which filtered uric acid is reabsorbed from the urine back into the blood. By blocking URAT1, Probenecid increases the fractional excretion of uric acid. Additionally, it inhibits OAT1, OAT3, and OAT4. The inhibition of OAT1 and OAT3 in the basolateral membrane prevents the active secretion of organic acids (like penicillins and cephalosporins) from the blood into the tubule, thereby increasing their plasma concentration.

The onset of the uricosuric effect occurs within 30 minutes of oral administration, with peak effects seen at 2 to 4 hours. The duration of action is approximately 8 to 12 hours. The relationship between dose and effect is non-linear; as the dose increases, the transporters become saturated, and the half-life of the drug extends. Probenecid does not have any anti-inflammatory or analgesic activity; its pharmacodynamic profile is strictly limited to renal transport modulation.

| Parameter | Value |

|---|---|

| Bioavailability | >90% (Oral) |

| Protein Binding | 75% - 95% (Albumin) |

| Half-life | 5 - 8 hours (Dose-dependent) |

| Tmax | 2 - 4 hours |

| Metabolism | Hepatic (Glucuronidation/Oxidation) |

| Excretion | Renal (<5% unchanged) |

• Molecular Formula: C13H19NO4S
• Molecular Weight: 285.36 g/mol
• Solubility: Practically insoluble in water; soluble in dilute alkali, alcohol, and chloroform.
• Structure: Probenecid is a benzoic acid derivative, specifically 4-[(dipropylamino)sulfonyl]benzoic acid. It contains a sulfonamide group, though it lacks the antibacterial properties of sulfonamide antibiotics.

Probenecid is the prototypical member of the uricosuric class of medications. Within the EPC (Established Pharmacologic Class) system, it is often grouped under Alkaloid [EPC] or simply as a Uricosuric. It is related to other transport inhibitors like sulfinpyrazone (now largely discontinued) and the newer agent lesinurad.